biostudies-literatureKlasener KStiftelserna Wilhelm och Martina LundgrensVetenskapsrådetSwedish Cancer FoundationStiftelsen Apotekare Hedbergs Fond för Medicinsk ForskningRoche Innovation Center ZurichBarncancerfondenKungl. Vetenskaps- och Vitterhets-Samhället i GöteborgIngaBritt och Arne Lundbergs ForskningsstiftelseÅke Wiberg StiftelseAdlerbertska Research FoundationReumatikerförbundetDeutsche ForschungsgemeinschaftStiftelsen Assar Gabrielssons Fonde70011https://www.ebi.ac.uk/biostudies/studies/S-EPMC11447455biostudies-literatureUnknown13(10)<h4>Objectives</h4>Paediatric Burkitt's lymphoma (pBL) is the most common childhood non-Hodgkin B-cell lymphoma. Despite the encouraging survival rates for most children, treating cases with relapse/resistance to current therapies remains challenging. CD38 is a transmembrane protein highly expressed in pBL. This study investigates the effectiveness of CD38-targeting monoclonal antibodies (mAbs), daratumumab and isatuximab, in impairing crucial cellular processes and survival pathways in pBL malignant cells.<h4>Methods</h4><i>In silico</i> analyses of patient samples, combined with <i>in vitro</i> experiments using the Ramos cell line, were conducted to assess the impact of daratumumab and isatuximab on cellular proliferation, apoptosis and the phosphoinositide 3-kinase (PI3K) pathway.<h4>RClinical & translational immunologyTargeting CD38 with monoclonal antibodies disrupts key survival pathways in paediatric Burkitt's lymphoma malignant B cells.PMC11447455BGR23‐0319 0464FB21‐1042018‐03128PR2020‐0147FB22‐70PR2018‐0170Herrmann NBoren JVisentini MLundqvist CReth MCamponeschi AAranburu AKlasener KSundell TManna PTForsman HFogelstrand LMartensson ILLjung Sass DJonsson CASundqvist MMellgren KGjertsson IGrimstad KEkwall OHaversen LMcGrath SfalseTargeting CD38 with monoclonal antibodies disrupts key survival pathways in paediatric Burkitt's lymphoma malignant B cells.<h4>Objectives</h4>Paediatric Burkitt's lymphoma (pBL) is the most common childhood non-Hodgkin B-cell lymphoma. Despite the encouraging survival rates for most children, treating cases with relapse/resistance to current therapies remains challenging. CD38 is a transmembrane protein highly expressed in pBL. This study investigates the effectiveness of CD38-targeting monoclonal antibodies (mAbs), daratumumab and isatuximab, in impairing crucial cellular processes and survival pathways in pBL malignant cells.<h4>Methods</h4><i>In silico</i> analyses of patient samples, combined with <i>in vitro</i> experiments using the Ramos cell line, were conducted to assess the impact of daratumumab and isatuximab on cellular proliferation, apoptosis and the phosphoinositide 3-kinase (PI3K) pathway.<h4>R2024-01-01T00:00:00Z20242026-06-14T05:21:06.946Z2025-04-04T02:30:03.751ZS-EPMC114474553936439310.1002/cti2.70011